Suhir Paul

Paul’s work as a Professor at the Universities of Nebraska and Texas has brought catabodies/E-vaccines from chemical curiosities to the verge of medical use. His research was funded continuously by the NIH, non-profit foundations and biotech companies since 1983. His early discovery patents were bought out (USD 21 MM) by Abgenix in 2001. He discovered harmful catabodies in autoimmune disease, progressing to devising our on-demand technology platform for generating catabodies and E-vaccines for disease treatment and prevention. He has authored ~200 original research articles and edited several books. Paul co-founded Covalent Bioscience. In 2018, he moved fulltime to Covalent to translate his know-how and inventions for medical benefits.